17th Expert Committee on the Selection and Use of Essential Medicines: Applications (Section 1-15)

• Section 16-29

Section 1: Anaesthetics

Section 2: Analgesics

Section 3: Antiallergics

Section 4: Antidotes

• Pralidoxime (Inclusion)

Section 5: Anticonvulsants/antiepileptics

• Lamotrigine (Inclusion)
• Lorazepam (Inclusion)
• Midazolam (Inclusion)

Section 6: Anti-infective medicines

• Amantadine and rimantadine (Inclusion)
• Antituberculosis medicines (Inclusion) -- Paediatrics [NEW]
• Artemether + lumefantrine (Inclusion) -- Paediatrics
• Atazanavir (Inclusion) -- [NEW]
• Liposomal amphotericin B (Inclusion) -- Paediatrics [NEW]
• Nifurtimox + eflornithine (Inclusion)
• Oseltamivir (Inclusion)
• Procaine benzylpenicillin (Review) -- (Paediatrics) [NEW]
• Protease inhibitors (Review)
• Rifabutin (Inclusion)
• Zanamivir (Inclusion)
• Zidovudine + lamivudine + abacavir (Inclusion) -- [NEW]

Section 7: Antimigraine medicines

• Ibuprofen (Inclusion) -- Paediatrics
• Sumatriptan (Inclusion)

Section 8: Antineoplastic

• Carboplatin (Inclusion)
• Hydroxycarbamide (Inclusion)
• Ifosfamide (Inclusion)
• Mesna (Inclusion)

Section 9: Antiparkinsonism medicines

Section 10: Medicines affecting the blood

• Tranexamic acid (Inclusion)

Section 11: Blood products

Section 12: Cardiovascular medicines

• Amiodarone (Inclusion)
• Captopril (Inclusion) -- Paediatrics
• Carvedilol (Inclusion) -- Paediatrics
• Hydrochlorothiazide (New formulations)
• Quinidine (Possible deletion)

Section 13: Dermatological medicines

Section 14: Diagnostic agents

Section 15: Disinfectants